Drug intelligence / Profile preview

AT-201

Development stage: Preclinical
Lead developer: Adept Biopharmaceutical and Technology
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AT-201 is a preclinical-stage trispecific antibody being developed by Adept Biopharmaceutical for the treatment of solid tumors. It is a key candidate within the company's Antibody-Based Cell-mediated Cytotoxicity (ABCC) trispecific antibody program. While the specific molecular targets of AT-201 remain proprietary and have not been disclosed in public pipeline documentation, the trispecific modality is designed to simultaneously engage multiple antigens or immune cell receptors to enhance therapeutic efficacy and overcome resistance mechanisms in the tumor microenvironment.

Beyond the preview

Go deeper on AT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-201.

Explore the full profile